Chronic Kidney Disease

September 27th 2024

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

September 6th 2024

Full traditional approval follows accelerated approval of the medication last year.

August 27th 2024

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

August 8th 2024

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.